Total Payments
$20,004
2024 Payments
$969.09
Companies
32
Transactions
423
Medicare Patients
5,179
Medicare Billing
$6.2M
Payment Breakdown by Category
Other$9,500 (47.5%)
Food & Beverage$7,652 (38.3%)
Travel$2,674 (13.4%)
Education$178.17 (0.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $9,500 | 6 | 47.5% |
| Food and Beverage | $7,652 | 407 | 38.3% |
| Travel and Lodging | $2,674 | 5 | 13.4% |
| Education | $178.17 | 5 | 0.9% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $13,942 | 74 | $0 (2024) |
| Amgen Inc. | $970.93 | 73 | $0 (2024) |
| Genentech USA, Inc. | $693.76 | 47 | $0 (2023) |
| Janssen Biotech, Inc. | $572.53 | 30 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $403.32 | 23 | $0 (2024) |
| PFIZER INC. | $378.85 | 25 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $349.68 | 24 | $0 (2024) |
| UCB, Inc. | $323.40 | 16 | $0 (2024) |
| Horizon Pharma plc | $293.93 | 12 | $0 (2018) |
| Lilly USA, LLC | $284.35 | 18 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $969.09 | 58 | ABBVIE INC. ($303.30) |
| 2023 | $1,232 | 45 | ABBVIE INC. ($249.08) |
| 2022 | $806.06 | 46 | Amgen Inc. ($125.88) |
| 2021 | $693.60 | 46 | Amgen Inc. ($170.71) |
| 2020 | $448.65 | 27 | Janssen Biotech, Inc. ($115.54) |
| 2019 | $812.18 | 56 | AbbVie, Inc. ($174.78) |
| 2018 | $8,450 | 60 | AbbVie, Inc. ($7,778) |
| 2017 | $6,593 | 85 | AbbVie, Inc. ($5,206) |
All Payment Transactions
423 individual payment records from CMS Open Payments — Page 17 of 17
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 05/08/2017 | E.R. Squibb & Sons, L.L.C. | ORENCIA (Biological) | Food and Beverage | Cash or cash equivalent | $2.99 | General |
| Category: Immunology | ||||||
| 05/03/2017 | Amgen Inc. | Enbrel (Biological), Prolia | Food and Beverage | In-kind items and services | $3.74 | General |
| Category: Inflammation | ||||||
| 04/28/2017 | UCB, Inc. | Cimzia (Drug) | Food and Beverage | In-kind items and services | $82.64 | General |
| Category: Immunology | ||||||
| 04/17/2017 | Lilly USA, LLC | FORTEO (Drug) | Food and Beverage | In-kind items and services | $14.02 | General |
| Category: Bone Muscle Joint | ||||||
| 04/17/2017 | Amgen Inc. | Enbrel (Biological), Prolia | Food and Beverage | In-kind items and services | $6.51 | General |
| Category: Inflammation | ||||||
| 04/12/2017 | E.R. Squibb & Sons, L.L.C. | ORENCIA (Biological) | Food and Beverage | Cash or cash equivalent | $10.75 | General |
| Category: Immunology | ||||||
| 04/05/2017 | Lilly USA, LLC | FORTEO (Drug) | Food and Beverage | In-kind items and services | $10.50 | General |
| Category: Bone Muscle Joint | ||||||
| 04/04/2017 | Celgene Corporation | Otezla (Drug) | Food and Beverage | In-kind items and services | $120.00 | General |
| Category: Dermatology | ||||||
| 04/04/2017 | Genentech USA, Inc. | Rituxan (Biological), Actemra | Food and Beverage | In-kind items and services | $3.83 | General |
| Category: BioOncology/Immunology | ||||||
| 03/29/2017 | Celgene Corporation | — | Food and Beverage | In-kind items and services | $9.10 | General |
| 03/22/2017 | Horizon Pharma plc | KRYSTEXXA (Drug) | Food and Beverage | In-kind items and services | $9.95 | General |
| Category: KRYSTEXXA | ||||||
| 03/20/2017 | Genentech USA, Inc. | Rituxan (Biological) | Food and Beverage | In-kind items and services | $22.17 | General |
| Category: BioOncology/Immunology | ||||||
| 03/14/2017 | E.R. Squibb & Sons, L.L.C. | ORENCIA (Biological) | Food and Beverage | Cash or cash equivalent | $5.65 | General |
| Category: Immunology | ||||||
| 03/08/2017 | Amgen Inc. | Enbrel (Biological), Prolia | Food and Beverage | In-kind items and services | $15.70 | General |
| Category: Inflammation | ||||||
| 03/01/2017 | E.R. Squibb & Sons, L.L.C. | ORENCIA (Biological) | Food and Beverage | Cash or cash equivalent | $5.23 | General |
| Category: Immunology | ||||||
| 02/22/2017 | Horizon Pharma plc | KRYSTEXXA (Drug) | Food and Beverage | In-kind items and services | $15.40 | General |
| Category: KRYSTEXXA | ||||||
| 02/10/2017 | UCB, Inc. | Cimzia (Drug) | Food and Beverage | In-kind items and services | $15.25 | General |
| Category: Immunology | ||||||
| 01/24/2017 | Amgen Inc. | Enbrel (Biological), Prolia | Food and Beverage | In-kind items and services | $5.22 | General |
| Category: Inflammation | ||||||
| 01/18/2017 | Lilly USA, LLC | FORTEO (Drug) | Food and Beverage | In-kind items and services | $14.03 | General |
| Category: Bone Muscle Joint | ||||||
| 01/17/2017 | Genentech USA, Inc. | Actemra (Biological) | Food and Beverage | In-kind items and services | $13.11 | General |
| Category: Immunology | ||||||
| 01/17/2017 | Genentech USA, Inc. | Actemra (Biological) | Food and Beverage | In-kind items and services | $0.59 | General |
| Category: Immunology | ||||||
| 01/12/2017 | Genentech USA, Inc. | Rituxan (Biological), Actemra | Food and Beverage | In-kind items and services | $8.11 | General |
| Category: BioOncology/Immunology | ||||||
| 01/12/2017 | Genentech USA, Inc. | Rituxan (Biological), Actemra | Food and Beverage | In-kind items and services | $0.89 | General |
| Category: BioOncology/Immunology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 23 | 1,307 | 179,233 | $8.4M | $2.1M |
| 2022 | 22 | 1,290 | 98,644 | $5.8M | $1.5M |
| 2021 | 24 | 1,329 | 90,515 | $5.3M | $1.5M |
| 2020 | 25 | 1,253 | 62,922 | $3.7M | $1.2M |
Total Patients
5,179
Total Services
431,314
Medicare Billing
$6.2M
Procedure Codes
94
All Medicare Procedures & Services
94 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2023 | 35 | 16,950 | $1.9M | $545,441 | 28.9% |
| J3262 | Injection, tocilizumab, 1 mg | Office | 2023 | 27 | 76,489 | $956,362 | $357,696 | 37.4% |
| J1602 | Injection, golimumab, 1 mg, for intravenous use | Office | 2023 | 44 | 28,879 | $1.5M | $305,674 | 20.1% |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | Office | 2023 | 52 | 11,535 | $1.8M | $288,399 | 16.1% |
| J9312 | Injection, rituximab, 10 mg | Office | 2023 | 21 | 3,750 | $642,000 | $218,625 | 34.1% |
| J0717 | Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2023 | 14 | 34,401 | $650,020 | $135,019 | 20.8% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 171 | 804 | $382,496 | $76,786 | 20.1% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 42 | 4,020 | $164,220 | $74,007 | 45.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 278 | 559 | $190,856 | $48,331 | 25.3% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 57 | 219 | $60,144 | $11,578 | 19.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 87 | 87 | $41,292 | $10,284 | 24.9% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 85 | 397 | $42,753 | $8,461 | 19.8% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 52 | 247 | $21,247 | $2,915 | 13.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 41 | 44 | $9,876 | $2,348 | 23.8% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 22 | 50 | $12,983 | $2,083 | 16.0% |
| 20611 | Aspiration and/or injection of fluid large joint using ultrasound guidance | Office | 2023 | 11 | 19 | $7,267 | $1,673 | 23.0% |
| 20604 | Aspiration and/or injection of fluid from small joint using ultrasound guidance | Office | 2023 | 17 | 24 | $6,242 | $1,514 | 24.3% |
| 76942 | Ultrasonic guidance for needle placement | Office | 2023 | 18 | 25 | $4,833 | $1,119 | 23.2% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 63 | 86 | $1,204 | $722.40 | 60.0% |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | Office | 2023 | 47 | 124 | $1,809 | $383.19 | 21.2% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 23 | 30 | $2,814 | $281.81 | 10.0% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 52 | 266 | $2,949 | $212.56 | 7.2% |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | Office | 2023 | 48 | 228 | $1,140 | $184.79 | 16.2% |
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2022 | 32 | 11,425 | $1.3M | $396,336 | 30.4% |
| J1602 | Injection, golimumab, 1 mg, for intravenous use | Office | 2022 | 40 | 26,300 | $1.4M | $306,876 | 22.4% |
About Dr. Diman Lamichhane, MD
Dr. Diman Lamichhane, MD is a Rheumatology healthcare provider based in Eugene, Oregon. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/23/2007. The National Provider Identifier (NPI) number assigned to this provider is 1700067360.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Diman Lamichhane, MD has received a total of $20,004 in payments from pharmaceutical and medical device companies, with $969.09 received in 2024. These payments were reported across 423 transactions from 32 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($9,500).
As a Medicare-enrolled provider, Lamichhane has provided services to 5,179 Medicare beneficiaries, totaling 431,314 services with total Medicare billing of $6.2M. Data is available for 4 years (2020–2023), covering 94 distinct procedure/service records.
Ad
Practice Information
- Specialty Rheumatology
- Other Specialties Rheumatology, Internal Medicine
- Location Eugene, OR
- Active Since 11/23/2007
- Last Updated 09/27/2025
- Taxonomy Code 207RR0500X
- Entity Type Individual
- NPI Number 1700067360
Products in Payments
- Humira (Biological) $3,467
- Enbrel (Biological) $526.62
- RINVOQ (Biological) $470.25
- Rituxan (Biological) $413.34
- ORENCIA (Biological) $403.32
- XELJANZ (Drug) $305.44
- SIMPONI ARIA (Biological) $293.31
- EVENITY (Biological) $291.60
- Cimzia (Drug) $278.52
- KRYSTEXXA (Biological) $226.32
- Actemra (Biological) $217.25
- KEVZARA SARILUMAB INJECTION (Biological) $198.75
- SKYRIZI (Biological) $198.07
- KRYSTEXXA (Drug) $198.02
- COSENTYX (Biological) $186.78
- TALTZ (Drug) $185.52
- Otezla (Drug) $172.08
- SAPHNELO (Biological) $171.49
- REMICADE (Biological) $157.03
- BENLYSTA (Biological) $126.60
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Rheumatology Doctors in Eugene
William Maier, Md, MD
Rheumatology — Payments: $5,266
Rheumatology $5,266
Sidney Cassell, Md, MD
Rheumatology — Payments: $1,818
Rheumatology $1,818
Simona Braun, Md, MD
Rheumatology — Payments: $1,765
Rheumatology $1,765
Sarah Cassell
Rheumatology — Payments: $1,444
Rheumatology $1,444
Hesham Elmergawy, M.d, M.D
Rheumatology — Payments: $879.81
Rheumatology $879.81
Dr. Norman Hudson, Md, MD
Rheumatology
Rheumatology